A Novel Diagnostic Target in the Hepatitis C Virus Genome

Citation for published version:

Digital Object Identifier (DOI):
10.1371/journal.pmed.1000031

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS Medicine

Publisher Rights Statement:
Copyright: © 2009 Drexler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
A Novel Diagnostic Target in the Hepatitis C Virus Genome

Jan Felix Drexler1,2,3, Bernd Kupfer2, Nadine Petersen1, Rejane Maria Tommasini Grotto4, Silvia Maria Corvino Rodrigues4, Klaus Grywna1, Marcus Panning1, Augustina Annan1, Giovanni Faria Silva4, Jill Douglas5, Evelyn S. C. Koay6,7, Heidi Smuts8, Eduardo M. Netto3, Peter Simmonds5, Maria Inês de Moura Campos Pardini4, W. Kurt Roth9, Christian Drosten2*

1 Clinical Virology Group, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany, 2 Institute of Virology, University of Bonn, Bonn, Germany, 3 Infectious Diseases Research Laboratory, University Hospital Prof. Edgard Santos, Federal University of Bahia, Salvador, Brazil, 4 University of São Paulo State (UNESP), Botucatu Medical School, Blood Transfusion Centre - Molecular Biology Laboratory and Internal Medicine Department, Botucatu, São Paulo, Brazil, 5 Virus Evolution Group, Centre for Infectious Diseases, University of Edinburgh, Edinburgh, United Kingdom, 6 Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, 7 Molecular Diagnosis Centre, National University Hospital, Singapore, 8 Division Medical Virology/National Health Laboratory Service, Department of Clinical Laboratory Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, 9 GFE Blut mbH, Frankfurt (Main), Germany

Funding: The Brazilian study was partially supported by a donation of reagents from Qiagen, Germany. The German study was supported by the German Ministry of Health (BMGS) as a part of funding of the National Reference Centre for Tropical Infections at the Bernhard Nocht Institute and by European Union contract number SSPE-CT-2005-022639. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

ABSTRACT

Background

Detection and quantification of hepatitis C virus (HCV) RNA is integral to diagnostic and therapeutic regimens. All molecular assays target the viral 5'-noncoding region (5'-NCR), and all show genotype-dependent variation of sensitivities and viral load results. Non-western HCV genotypes have been under-represented in evaluation studies. An alternative diagnostic target region within the HCV genome could facilitate a new generation of assays.

Methods and Findings

In this study we determined by de novo sequencing that the 3'-X-tail element, characterized significantly later than the rest of the genome, is highly conserved across genotypes. To prove its clinical utility as a molecular diagnostic target, a prototype qualitative and quantitative test was developed and evaluated multicentrically on a large and complete panel of 725 clinical plasma samples, covering HCV genotypes 1–6, from four continents (Germany, UK, Brazil, South Africa, Singapore). To our knowledge, this is the most diversified and comprehensive panel of clinical and genotype specimens used in HCV nucleic acid testing (NAT) validation to date. The lower limit of detection (LOD) was 18.4 IU/ml (95% confidence interval, 15.3–24.1 IU/ml), suggesting applicability in donor blood screening. The upper LOD exceeded 10^9 IU/ml, facilitating viral load monitoring within a wide dynamic range. In 598 genotyped samples, quantified by Bayer VERSANT 3.0 branched DNA (bDNA), X-tail-based viral loads were highly concordant with bDNA for all genotypes. Correlation coefficients between bDNA and X-tail NAT, for genotypes 1–6, were: 0.92, 0.85, 0.95, 0.91, 0.95, and 0.96, respectively; X-tail-based viral loads deviated by more than 0.5 log10 from 5'-NCR-based viral loads in only 12% of samples (maximum deviation, 0.85 log10). The successful introduction of X-tail NAT in a Brazilian laboratory confirmed the practical stability and robustness of the X-tail-based protocol. The assay was implemented at low reaction costs (US$7.80 per sample), short turnover times (2.5 h for up to 96 samples), and without technical difficulties.

Conclusion

This study indicates a way to fundamentally improve HCV viral load monitoring and infection screening. Our prototype assay can serve as a template for a new generation of viral load assays. Additionally, to our knowledge this study provides the first open protocol to permit industry-grade HCV detection and quantification in resource-limited settings.

The Editors’ Summary of this article follows the references.
Introduction

Hepatitis C virus (HCV) is one of the leading causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [1,2]. Seroprevalence studies suggest that at least 170 million individuals have been infected worldwide [3]. The incidence of new HCV infections has decreased in affluent countries owing to screening of blood products, but an increase of global patient numbers is still expected [1–3]. At present, six genotypes and more than 30 subtypes are well characterized, with an overall nucleotide diversity of 31%–33% between genotypes and 20%–25% between subtypes [4]. Diagnostic detection of HCV RNA identifies an infection weeks to months before a detectable antibody response. To prevent transmission by transfusion of viremic blood, nucleic acid testing (NAT) of blood donors has become a routine procedure in industrialized countries. As a marker of treatment success, the decrease of virus RNA concentration (viral load) as measured by quantitative NAT has become a clinical gold standard [5,6]. For these molecular tests, several generations of qualitative and/or quantitative HCV NAT assays have been in use. The most recent improvement was the introduction of real-time PCR-based assays [7–10]. However, even the latest versions of assays diverge in performance between different genotypes [11–21]. This divergence is of strategic clinical relevance as success of therapy varies between HCV genotypes [22]. Consistently, genotypes other than those occurring in industrialized countries have been under-represented in clinical evaluation studies [23]. Along with high costs for commercial assays, genotype variation complicates the initiation of successful treatment programmes in several less-affluent countries. In analogy to HIV treatment, open-protocol and low-cost HCV viral load technology would be desirable [24–28].

Unfortunately, the design of both commercial and in-house tests for HCV suffers from properties of the viral 5′-noncoding region (5′-NCR). This region is thought to be the most conserved portion of the HCV genome [29] and is targeted by all assays. Test manufacturers have made substantial efforts to optimize 5′-NCR target sites, keeping them unpublished for all current commercial assays. Still, there seem to be remaining issues with these tests, as exemplified by the discontinuation of a new real-time PCR-based assay in 2004 after initial introduction in blood screening [13,30]. One of the most important issues may be the existence of complex secondary structures due to the 5′-NCR’s function as an internal ribosomal entry site for genome translation [31]. These secondary structures may interfere in complex ways with primer or probe binding.

Due to notorious problems with the 5′-NCR, a different target region would be beneficial. However, viral genes downstream of the 5′-NCR are not useful as diagnostic targets because of their nucleotide variability [4,32]. In the mid 1990s, molecular biology studies on the HCV replication cycle revealed that the genome carries an additional element in its 3′-UTR downstream of the poly-U tract, the so-called X-tail [33,34]. The biological function of the X-tail is not completely understood, but it has been shown that it is involved in several crucial steps throughout the HCV life cycle, involving both RNA-RNA and RNA-protein interactions [35–38]. The X-tail has been suggested to be highly conserved [35,36], but it is unclear whether other issues (e.g., secondary structures) might interfere with its molecular detection. It may be due to lack of available sequence information across all genotypes that the X-tail has been neglected as a diagnostic target so far. In this study we explored its utility for HCV detection and quantification by sequencing the X-tail from a broad and complete panel of HCV genotypes. To assess its diagnostic utility, we then developed an X-tail-based viral load assay that fulfills the same technical standards as commercial assays currently in clinical use. Clinical validation involved 725 stored samples across HCV genotypes 1–6 from patients from four continents (Germany, UK, South Africa, Singapore, and Brazil). Technical robustness was demonstrated by implementation of the assay in a routine viral load laboratory in Brazil.

Materials and Methods

Reference Plasma

The World Health Organization (WHO) international standard reagent 96/798 was obtained from National Institute for Biological Standards and Control, (Hertfordshire, UK) [39]. It contained 50,000 international units (IU) of HCV, genotype 1a, per milliliter. A genotype reference plasma panel was obtained from the German Hepatitis C Reference Center at the University of Essen, including lyophilized human plasma containing HCV genotypes 1a, 1b, 2a, 2b, 2c, 2i, 3a, 4d, 5a, and 6e. Genotypes as determined by commercial assays (Inno-Lipa HCV2, GEN-ETI-K DEA) and in-house sequencing, as well as viral loads as determined by both the Roche Amplicor 2.0 (Amplicor) and the Bayer VERSANT bDNA 3.0 (branched DNA [bDNA]) systems were provided with this panel (http://www.uni-essen.de/virologie/hcv__hc-panel.html). Only the samples mentioned in this paragraph were used for the technical development of the assay.

Patient Plasma and Commercially Available Viral Load and Genotyping Assays

For validation of the assay, a total of 725 human plasma samples (one sample per patient) were studied. Of these, 598 were obtained from routine clinical testing in Germany, UK, South Africa, Singapore, and Brazil (n = 319, 62, 102, 52, 46, and 17 of HCV genotypes 1, 2, 3, 4, 5, and 6, respectively). These stored samples had been selected because of their known genotypes, and were collected at the University of Bonn, Germany (n = 530, HCV genotypes 1 to 4, sampled from 2003 to 2007), the University of Cape Town, South Africa (n = 46, genotype 5, sampled from 1996 to 2007), the National University of Singapore (n = 9, genotypes 3k and 6, sampled from 2006 to 2007), and the University of Edinburgh, UK (n = 13, genotype 6, sampled from 1999 to 2004). Samples were generally taken at the time of genotyping, i.e., immediately before the beginning of therapy. We did not accept recorded genotype information from earlier or later samples from a given patient. An additional set of plasma samples, collected from 2005 to 2007 at the University of São Paulo State, Brazil, contained 127 nongenotyped samples from patients during HCV therapy. All samples were anonymized and approval was obtained by the ethical committees of the University of Bonn Medical Centre, Bonn, Germany; the University of São Paulo State (UNESP); Botucatu Medical School, Botucatu, São Paulo, Brazil; and the Federal University of Bahia Medical School, Salvador, Bahia, Brazil. Viral loads in all samples were
determined at the University of Bonn with bDNA on a VERSANT 440 Molecular System. Samples were genotyped by the VERSANT HCV Genotype assay (Line Probe assay [LiPA]) (Bayer Diagnostics). Genotyping of the South African and British samples was done by restriction fragment length polymorphism (RFLP), as previously described [40,41] and confirmed by LiPA. The genotypes of all samples from Singapore were confirmed by sequencing of the 5'-NCR and nonstructural protein 5b (NS5b) domains [42]. Samples were stored at −20 °C until quantification with the X-tail real-time reverse transcriptase (RT)-PCR assay (X-tail RT-PCR). All Brazilian samples were tested by bDNA on a VERSANT 340 Molecular System and X-tail RT-PCR in the local laboratory in Brazil.

Quantification of HCV Viral Load by X-Tail RT-PCR
Reactions of 50 μl contained 20 μl of RNA extract, 5× reaction buffer (Qiagen One-step RT-PCR kit), 200 nM of each dNTP, 200 nM of primer XTF5 (GTGGGCTCTGACCTTAGCCCTAGT), 300 nM of primer HCMgR2 (TGCGGCTCACGGACCTTT), 100 nM of HCV-specific probe HCVMG02 (FAM-CACGGCTAGCTGTG-Black Hole Quencher 2/Minor groove binder), 100 nM of Internal Control-probe YFPY (VIC-ATCGTTCGTTGAGCGATTAGCAG-Black Hole Quencher 1), and 2 μl of Enzyme Mix. Thermal cycling was done on Applied Biosystems 7700 or 7500 SDS instruments under the following conditions: 55 °C, 10 min; 95 °C, 15 min; 45 cycles at 94 °C, 10 s and 58 °C, 15 s.

Computing
Statistical analyses were performed with the SPSS 13 (SPSS). Alignments were generated using BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). Sequences were analyzed using the Lasergene software package (DNASTAR). All database work was performed online on Los Alamos National Laboratory (LANL) (http://hcv.lanl.gov/content/hcv-index) and euHCV (http://euhcvdb.ibcp.fr/euhcvdb) domains.

Supplemental Materials and Methods
A STARD diagram and checklist are included in Figure S1 and Text S1. A more detailed description of the X-tail NAT assay including protocols for RNA extraction and data on technical performance are provided in Text S2. A bench protocol and instructions for requesting controls is provided in Text S3.

Accession Numbers
Sequences determined in this study have been submitted to GenBank (http://www.ncbi.nlm.nih.gov/Genbank) under accession numbers EU835523-EU835532.

Results
Analysis of the X-Tail Region
In order to examine the conservedness of the X-tail region, a nucleic acid sequence alignment was generated that contained all X-tail sequences stored in the LANL and euHCV databases as of January 2007. These databases comprised sequences classified as genotypes 1, 2, and 3. Sets of sequencing primers for the ultimate 3'-end of the genome were identified, and the X-tail was sequenced from reference plasma samples of HCV genotypes 1–6. Together with one outlier sequence taken from the initial characterization study on the X-tail [33] that was found later on to correspond to genotype 4 (PS, unpublished data), these novel sequences were added to the alignment. As shown in Figure 1, the degree of conservedness in the X-tail was comparable to that of the 5'-NCR, which is the target of all existing viral load assays.

Experimental Identification of a Diagnostic Target Region within the X-Tail
The complete 3'-UTR alignment was evaluated as a target for real-time PCR design. Since primer design software was not able to identify suitable candidate oligonucleotides, in a first approach five forward primers, five reverse primers, and two probes were selected upon inspection of the alignment. All of the 50 resulting real-time PCR sets were tested experimentally for reaction efficiency. However, even after selection of the most effective oligonucleotides and optimization of reaction conditions, the lower limit of detection (LOD) did not fall below 150 IU/ml (see Text S2 for additional...
information on technical evaluation procedures). Since primers had a perfect match with the target sequence, the limitation in sensitivity was ascribed to RNA secondary structures possibly interfering with oligonucleotide hybridization.

RNA secondary structures of both the X-tail and the 5'-NCR were modeled at PCR primer annealing conditions (58°C and 50 mM ion concentration) using MFOLD [43]. In the 5'-NCR, secondary structures in all genotypes were almost completely dissolved, but still a few stable stem-loop elements remained. Of note, some of these fell in the conserved regions targeted by a prototypic 5'-NCR assay, the Roche Amplicor Monitor, and probably also the later generation COBAS TaqMan system [13]. For the X-tail, a 10-nucleotide-stem element in the stem-loop 1 region towards the 3' end of the X-tail was predicted to be stable at the same conditions. Figure 2 shows the structure predictions with exemplified oligonucleotides for X-tail and 5'-NCR. It was concluded that stable stem structures were likely to interfere with binding of all antisense primers and most of the probes used up to this point.

Prototype Viral Load Assay Based on the HCV X-Tail

Consequently, the antisense primer and probe binding sites were moved further upstream into the amplicon. Out of several new candidate primers and probes, an oligonucleotide combination was determined that provided very high amplification efficiency (final assay oligonucleotides as shown in the Materials and Methods section). These primers and probe were directly adjacent, without unoccupied nucleotides between them. Very few nucleotide mismatches occurred with any of the sequences taken from GenBank or determined from reference plasma (see Figure 2). According to established data, these mismatches were highly unlikely to interfere with assay performance [44–46].

To assess the diagnostic applicability of the X-tail, this PCR set was developed into a clinical-grade prototype assay. The input RNA volume was maximized to 20 μl in a 50-μl assay volume, and the chemistry was adjusted for use with a semi-automated nucleic acids extraction. In order to detect PCR inhibition, a competitive internal control was incorporated. It was amplified by the same primers as the diagnostic target but was detected by a probe of different sequence composition and different fluorescent labeling. To enhance assay stability, control RNA was formulated to be nuclease resistant and added at working concentration to all reactions at the lysis buffer stage. As a reference standard for viral loads, a noninfectious and stable copy of the HCV 1a X-tail was cloned.
in an armored RNA phage (refer to Text S2 for synthesis and calibration of internal control and reference standard).

Before evaluation of its technical and clinical performance, the specificity of the assay for HCV was confirmed on cell culture supernatants or sera containing the following 

**Flaviviridae** species: dengue virus 1, 2, 3, and 4; yellow fever virus; tick-borne encephalitis virus; St. Louis encephalitis virus; West Nile virus; and hepatitis G virus (HCV)/GB virus-C. Due to frequent co-infection of patients with HIV-1 and HCV, an HIV-1 genotype reference panel comprising 11 HIV-1 genotypes from groups M, N, and O [47] was acquired from National Institute for Biological Standards and Control (product code 01/466) and tested with X-tail RT-PCR. High RNA content in all of these materials was confirmed by a flavivirus genus-specific RT-PCR and an HIV-1 in-house real time RT-PCR assay [28,48]. No nonspecific amplification occurred with any of these materials (unpublished data).

**Table 1.** Lower LOD by HCV Genotype

<table>
<thead>
<tr>
<th>HCV RNA Input (IU/ml)</th>
<th>Hit Rate in Genotype Reference Samples</th>
<th>1a</th>
<th>1b</th>
<th>2a</th>
<th>2b</th>
<th>2c</th>
<th>3i</th>
<th>3a</th>
<th>4</th>
<th>5a</th>
<th>6</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td></td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>50/50</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
<td>46/50</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>3/5</td>
<td>2/5</td>
<td>5/5</td>
<td>1/5</td>
<td>5/5</td>
<td>3/5</td>
<td>5/5</td>
<td>2/5</td>
<td>3/5</td>
<td>2/5</td>
<td>30/50</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>1/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>2/5</td>
<td>3/5</td>
<td>3/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>9/50</td>
</tr>
<tr>
<td>LOD**</td>
<td></td>
<td>11.0</td>
<td>7.5</td>
<td>4.5</td>
<td>22.5</td>
<td>8.9</td>
<td>33.6</td>
<td>3.1</td>
<td>7.5</td>
<td>22.6</td>
<td>22.7</td>
<td>18.4</td>
</tr>
</tbody>
</table>

**a**Based on Bayer VERSANT bDNA 3.0 viral load assay.  
**LODb** at 95% probability, Probit analysis (see Text S2).

**Clinical Sensitivity**

Because correlation analysis only included samples that were positive in both tests, it did not reflect overall clinical sensitivity. A comparison of qualitative detection rates is shown in Table 2. Sixteen of a total of 598 samples (2.68%) were below the detection limit of bDNA but detectable by X-tail RT-PCR at a median viral load of 284 IU/ml. Three of these samples had viral loads that should have been detectable by bDNA, according to its LOD (615 IU/ml). Two samples were negative by X-tail RT-PCR despite RNA detection by bDNA at viral loads of 989 and 4,681 IU/ml, respectively.

A total of 15 samples had viral loads above the upper cutoff of bDNA, requiring predilution and repetition of the bDNA assay. All of them were quantifiable by X-tail RT-PCR upon first testing.
Potential for Implementation in Resource-Limited Settings

Affordable viral load monitoring would be desirable in resource-limited settings with high HCV prevalence. To evaluate whether the X-tail prototype assay would provide adequate stability and quality in comparison to 5'NCR-based assays, it was implemented in a diagnostic center involved in the Brazilian HCV treatment program. Protocols, controls, and standards for X-tail NAT were provided to the laboratory in Brazil. All other reagents were purchased locally. Plasma samples from 127 patients were tested by bDNA and X-tail NAT. The correlation coefficient between viral loads obtained with both assays was 0.97 (p<0.001) at a mean quantitative difference of 0.05 log10 (SD 0.018). As shown in Figure 5, almost all quantitative differences were below 0.5 log10. Only four outlier samples occurred, with deviations to higher and lower quantification results of up to 1 log10 in X-tail RT-PCR.

Discussion

In this study we have identified a new diagnostic target region in the HCV genome. A prototype RT-PCR assay based on the HCV X-tail proved to be highly sensitive (18.4 IU/ml, 95% probit probability), robust against genotype variation, and highly precise in virus quantification. The assay was efficiently implemented and projected to be highly cost efficient in an emerging country setting. These data may assist in translating state-of-the-art diagnostic technology to less affluent settings.

The X-tail region of the HCV genome has been known for several years [33,34] but has not been used as a diagnostic target so far. Its biological functions are now becoming clearer, and it is likely that its role in the virus life cycle involves both RNA and protein interactions. The three X-tail stem-loop structures (SL1–3) seem to be involved in negative-strand synthesis and significantly enhance HCV replication by means of binding to ribosomal and other cellular proteins [35–38]. A kissing-loop interaction between an X-tail stem-loop structure (SL2) and an RNA loop within the non-structural protein 5b (NS5b) region was shown to be essential for HCV replication [52]. These multiple mechanisms of interaction imply a high degree of conservedness in the X-
tail, which could indeed be confirmed for all genotypes in this study. As anticipated [32,53], the region proved as conserved as the 5’-NCR across all genotypes, and seemed to exhibit less problematic structural features than the 5’-NCR.

To circumvent the limitations that the 5’-NCR presents in diagnostics, we have established the HCV X-tail as a target for molecular detection and quantification. Initially we could not be sure about its utility for several reasons implied by its biological functions. A possible limitation could have been its position at the end of the genome and beyond the poly-U tract, making the X-tail prone to nuclease degradation. Moreover, due to its functions as a 3’-element it could have been associated strongly with viral or cellular proteins. Although we could not investigate these issues in our study, we are confident about its diagnostic utility from the clinical part of our study, showing that X-tail-based viral loads were highly concordant with results from bDNA testing, bDNA was chosen as a gold standard because it uses multiple probes associated strongly with viral or cellular proteins.

We have incorporated all of these features in the open protocol HCV X-tail assay. A second issue in using in-house diagnostics, we have established the HCV X-tail as a target for molecular detection and quantification. Initially we could not be sure about its utility for several reasons implied by its biological functions. A possible limitation could have been its position at the end of the genome and beyond the poly-U tract, making the X-tail prone to nuclease degradation. Moreover, due to its functions as a 3’-element it could have been associated strongly with viral or cellular proteins. Although we could not investigate these issues in our study, we are confident about its diagnostic utility from the clinical part of our study, showing that X-tail-based viral loads were highly concordant with results from bDNA testing, bDNA was chosen as a gold standard because it uses multiple probes associated strongly with viral or cellular proteins.

Table 2. Detection of HCV by X-Tail RT-PCR Versus bDNA

<table>
<thead>
<tr>
<th>Sample Testing Results</th>
<th>X-Tail RT-PCR</th>
<th>bDNA</th>
<th>n Samples</th>
<th>Median Viral Load (IU/ml)</th>
<th>Range Viral Load (IU/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>Positive</td>
<td>551</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Negative</td>
<td>Negative</td>
<td>14</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Positive</td>
<td>Negative</td>
<td>16</td>
<td>284</td>
<td>43–1,816,128</td>
<td>989–6,481</td>
</tr>
<tr>
<td>Negative</td>
<td>Positive</td>
<td>2</td>
<td>2,835</td>
<td>251,662–196,797,600</td>
<td>—</td>
</tr>
<tr>
<td>Positive</td>
<td>Overflowb</td>
<td>15</td>
<td>16,124,130</td>
<td>251,662–196,797,600</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>—</td>
<td>598</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Median HCV RNA IU/ml in the positive assay when below LOD in compared assay (<615 IU/ml for bDNA 3.0 and <46 IU/ml for X-tail RT-PCR).

bCould not be quantified due to viral loads >7,692,308 IU/ml (viral load was determined a posteriori by predilution).
assays is quality control, which is shifted largely to the production process in commercial kits, but can be managed at the laboratory level if appropriate quality control procedures are in place. In the context of HIV viral load monitoring, we and others have demonstrated that in-house testing in emerging countries is feasible in well-managed laboratories [24,25,27,28]. The potential for translation of the assay was demonstrated by implementation in a Brazilian laboratory and on-site comparison against the Bayer bDNA assay. X-tail RT-PCR had short turnover times (2.5 h for up to 96 samples) and was implemented from provided protocols without technical difficulties. Overall results suggest that X-tail RT-PCR is suitable for the Brazilian setting, even though genotyping was not feasible at the study site. The overall HCV genotype distribution in São Paulo state is known to be approximately 65%, 5%, and 30% of genotypes 1, 2, and 3, respectively [60]. Reaction costs of the assay ranged around US$8.70 per sample, or 8.1% of the current viral load costs in Brazil. It should be mentioned that under European conditions, an additional service license fee would apply, increasing the cost of one assay to US$18 per sample (refer to Table 3 for an estimation of costs).

Finally, HCV is an important issue for blood safety in emerging countries. Again, Brazil provides an example representative of many other emerging countries. An urgent federal decree in 2003 demanded the general testing of donated blood for HCV by NAT [61], but this strategy has not yet been implemented. According to estimates by the Brazilian Ministry of Health, it would cost about US$40 million to screen 4 million blood donations annually [62].

We previously demonstrated the feasibility of in-house testing of blood donors for HCV by NAT methods [63]. Due to the high sensitivity of X-tail RT-PCR (18.4 IU/ml), the prototype assay could be used for testing pooled blood donor samples. With the well-established approach of pooling 24 donors prior to NAT testing [64], the projected LOD would be 441 IU/ml per donor (18.4 IU/ml × 24). This projection would match the sensitivity achieved with pooled blood donor screening in Europe [65,66] and North America [64,67]. Calculating the cost for one X-tail NAT assay at US$10 (US$8.70 for RT-PCR according to Table 3, plus US$1.30 for extra consumables due to pooling), and assuming 20% additional costs for controls and confirmatory testing, 24-donor pool testing by X-tail RT-PCR would amount to US$2

Table 3. Approximate Pricing of HCV Viral Load Assays, US Dollars, without Taxes

<table>
<thead>
<tr>
<th>Item</th>
<th>X-Tail RT-PCR Germany</th>
<th>Roche Cobas Amplicor, Brazil</th>
<th>Bayer bDNA, Brazil</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA preparation</td>
<td>2.70a</td>
<td>Included</td>
<td>Included</td>
</tr>
<tr>
<td>Reagents</td>
<td>4.20</td>
<td>Included</td>
<td>Included</td>
</tr>
<tr>
<td>Consumables and controls</td>
<td>1.80</td>
<td>0.80</td>
<td>0.80</td>
</tr>
<tr>
<td>License fees</td>
<td>10.00</td>
<td>Included</td>
<td>Included</td>
</tr>
<tr>
<td>Total</td>
<td>18.70</td>
<td>106.80</td>
<td>106.80</td>
</tr>
</tbody>
</table>

*aBased on current conditions in Germany.
*bCurrent conditions for the São Paulo State Viral Hepatitis Network (unpublished data based on personal communications [RMTG and MIMCP]; see also [68]). Purchase by laboratories outside this privileged network may involve higher prices up to about US$190 per test.
*cThese items are included in the cost of the commercial assay.
*dService licence fees for using the generic 5'-nuclease probe format.

doi:10.1371/journal.pmed.1000031.t003
million per 4 million donations annually (4 million/24 × US$10 × 1.2). This means a reduction down to 5% of the current economic estimate. In view of the technical robustness and transferability of the assay described in this report, we believe that such a strategy could be a realistic approach in emerging countries aiming to increase blood safety through the introduction of HCV NAT.

Supporting Information

Found at doi:10.1371/journal.pmed.1000031.sd001 (29 KB DOC).
Alternative Language Abstract A2. Translation of the Abstract into German by Felix Drexler and Christian Drosten
Found at doi:10.1371/journal.pmed.1000031.sd002 (29 KB DOC).
Alternative Language Abstract A3. Translation of the Abstract into Portuguese by Felix Drexler and Maria Inez Pardini
Found at doi:10.1371/journal.pmed.1000031.sd003 (31 KB DOC).
Alternative Language Abstract A4. Translation of the Abstract into Spanish by Oscar Martinez Martinez
Found at doi:10.1371/journal.pmed.1000031.sd004 (27 KB DOC).

Figure S1. STARD Diagram
Found at doi:10.1371/journal.pmed.1000031.sg001 (11 KB PDF).

Text S1. STARD Checklist
Found at doi:10.1371/journal.pmed.1000031.s0005 (18 KB PDF).

Text S2. Detailed Description of the X-tail NAT Assay
Found at doi:10.1371/journal.pmed.1000031.s0006 (696 KB DOC).

Text S3. Bench Protocol and Instructions for Requesting Controls
Found at doi:10.1371/journal.pmed.1000031.s0007 (86 KB PDF).

Acknowledgments

We are grateful to technical staff at the involved institutions.

Author contributions.

JFD and CD conceived and designed the experiments. JFD, BK, NP, RMTG, SMCR, KG, MP, AA, GFS, JD, ESCK, HS, PS, MiIDMCP, and WKR performed the experiments. JFD, EMN, and CD analyzed the data. BK, RMTG, SMCR, GFS, JD, ESCK, HS, PS, MiIDMCP, and WKR contributed materials. JFD and CD wrote the paper.

References


Novel Diagnostic HCV Target
Editors’ Summary

Background. About 3% of the world’s population (170 million people) harbor long-term (chronic) infections with the hepatitis C virus (HCV) and about 3–4 million people are newly infected with this virus every year. HCV—a leading cause of chronic hepatitis (inflammation of the liver)—is spread through contact with the blood of an infected person. Globally, the main routes of transmission are the use of unscreened blood for transfusions and the reuse of inadequately sterilized medical instruments, including needles. In affluent countries, where donated blood is routinely screened for the presence of HCV, most transmission is through needle sharing among drug users. The risk of sexual and mother-to-child transmission of HCV is low. Although HCV infection occasionally causes an acute (short-lived) illness characterized by tiredness and jaundice (yellow eyes and skin), most newly infected people progress to a symptom-free, chronic infection that can eventually cause liver cirrhosis (scarring) and liver cancer. HCV infections can be treated with a combination of two drugs called interferon and ribavirin, but these drugs are expensive and are ineffective in many patients.

Why Was This Study Done? An effective way to limit the global spread of HCV might be to introduce routine screening of the blood that is used for transfusions in developing countries. In developed countries, HCV screening of blood donors use expensive, commercial “RT-PCR” assays to detect small amounts of HCV ribonucleic acid (RNA; HCV stores the information it needs to replicate itself—as a sequence of “ribonucleotides”). All the current HCV assays, which can also quantify the amount of viral RNA in the blood (the viral load) during treatment, detect a target sequence in the viral genome called the 5’-noncoding region (5’-NCR). However, there are several different HCV “genotypes” (strains). These genotypes vary in their geographical distribution and, even though the 5’-NCR sequence is very similar (highly conserved) in the common genotypes (HCV genotypes 1–6), the existing assays do not detect all the variants equally well. This shortcoming, together with their high cost, means that 5’-NCR RT-PCR assays are not ideal for use in many developing countries. In this study, the researchers identify an alternative diagnostic target sequence in the HCV genome—the 3’-X-tail element—and ask whether this sequence can be used to develop a new generation of tests for HCV infection that might be more appropriate for use in developing countries.

What Did the Researchers Do and Find? The researchers determined the RNA sequence of the 3’-X-tail element in reference samples of the major HCV genotypes and showed that this region of the HCV genome is as highly conserved as the 5’-NCR. They then developed a prototype X-tail RT-PCR assay and tested its ability to detect small amounts of HCV and to measure viral load in genotype reference samples and in a large panel of HCV-infected blood samples collected in Germany, the UK, Brazil, South Africa, and Singapore. The new assay detected low levels of HCV RNA in all of the genotype reference samples and was also able to quantify high RNA concentrations. The viral load estimates it provided for the clinical samples agreed well with those obtained using a commercial assay irrespective of the sample’s HCV genotype. Finally, the X-tail RT-PCR assay gave similar results to a standard assay at a fraction of the cost when used to measure viral loads in a Brazilian laboratory in an independent group of 127 patient samples collected in Brazil.

What Do These Findings Mean? These findings suggest that the HCV 3’-X-tail element could provide an alternative target for screening blood samples for HCV infection and for monitoring viral loads during treatment, irrespective of HCV genotype. In addition, they suggest that X-tail RT-PCR assays may be stable and robust enough for use in laboratories in emerging countries. Overall, these findings should stimulate the development of a new generation of clinical HCV assays that, because the protocol used in the X-tail assay is freely available, could improve blood safety in developing countries by providing a cheap and effective alternative to existing proprietary HCV assays.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1000031.

- The World Health Organization has a fact sheet about hepatitis C (in English and French)
- The US Centers for Disease Control and Prevention provides information on hepatitis C for the public and for health professionals (information is also available in Spanish)
- The US National Institute of Diabetes and Digestive and Kidney Diseases provides basic information on hepatitis C (in English and Spanish)
- The MedlinePlus Encyclopedia has a page on hepatitis C; MedlinePlus also provides links to further information on hepatitis C (in English and Spanish)